The present study aimed to clarify the hypothesis that auger emitter 125 I particles in combination with PARP inhibitor Olaparib could inhibit pancreatic cancer progression by promoting antitumor immune response. Pancreatic cancer cell line (Panc02) and mice subcutaneously inoculated with Panc02 cells were employed for the in vitro and in vivo experiments, respectively, followed by 125 I and Olaparib administrations. The apoptosis and CRT exposure of Panc02 cells were detected using flow cytometry assay. QRT-PCR, immunofluorescence, immunohistochemical analysis, and western blot were employed to examine mRNA and protein expression. Experimental results showed that 125 I combined with Olaparib induced immunogenic cell death and affected antigen presentation in pancreatic cancer. 125 I in combination with Olaparib influenced T cells and dendritic cells by up-regulating CD4, CD8, CD69, Caspase3, CD86, granzyme B, CD80, and type I interferon (IFN)-γ and down-regulating Ki67 in vivo. The combination also activated the cyclic GMP-AMP synthase stimulator of IFN genes (Sting) pathway in Panc02 cells. Moreover, Sting knockdown alleviated the effect of the combination of 125 I and Olaparib on pancreatic cancer progression. In summary, 125 I in combination with Olaparib inhibited pancreatic cancer progression through promoting antitumor immune responses, which may provide a potential treatment for pancreatic cancer.
Keyphrases
- immune response
- dendritic cells
- cell cycle arrest
- cell death
- induced apoptosis
- endoplasmic reticulum stress
- signaling pathway
- flow cytometry
- oxidative stress
- pi k akt
- toll like receptor
- heart failure
- high throughput
- regulatory t cells
- type diabetes
- cell proliferation
- staphylococcus aureus
- south africa
- diabetic rats
- high glucose
- pseudomonas aeruginosa
- adipose tissue
- climate change
- risk assessment
- neoadjuvant chemotherapy
- skeletal muscle
- innate immune
- locally advanced
- binding protein
- dna methylation
- stress induced